| Drug Name | Tasigna (Nilotinib) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Patient Card
Direct Healthcare Professional Communication DHPC
Healthcare provider guide
|
| Specialty (Theraputic area) |
Hematology
Oncology
|
| Risk |
Risk of hepatitis B reactivation QT prolongation . Cardiovascular events Hepatic transaminase and bilirubin elevations. Uncontrolled or significant cardiac disease/cardiac failure.Uncontrolled or significant cardiac disease/cardiac failure Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®
|
| patient guide |
|
| Health care provider guide |
|
| Dear Healthcare provider letter DHPC |
|